Epiminder has announced the first implantation of its Minder System in the US, a device developed for ongoing monitoring of epilepsy.
The procedure took place at the Perelman School of Medicine at the University of Pennsylvania, marking the site as the initial participant in the diagnosing epilepsy to effect change (DETECT) study.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Additionally, Beth Israel Deaconess Medical Center, Mayo Clinic Jacksonville, Mayo Clinic Phoenix, and Mayo Clinic Rochester are participating in the study and are currently recruiting patients.
The DETECT study is the first randomised controlled trial to directly compare patients implanted with the Minder System against those who receive standard care monitoring.
The aim is to identify clinically actionable events in individuals with drug-resistant epilepsy. In this six-month study, up to 210 patients will be implanted at a maximum of 25 sites across the US.
The primary goal of the research is to demonstrate that continuous electroencephalogram (EEG) monitoring provides superior identification of clinically actionable events compared to standard care for patients with drug-resistant epilepsy.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe study intends to address existing limitations in long-term EEG monitoring, which is often necessary for informed management decisions.
Epiminder CEO Rohan Hoare said: “This first US implant of our Minder device marks a watershed moment for Epiminder and the global epilepsy community. We are excited to take the next step in translating years of rigorous scientific development and clinical validation into real-world impact for patients who have exhausted traditional monitoring options.
“Dr Ganguly and her team at Penn Medicine represent the exceptional clinicians who will help us begin to unlock Minder’s full potential. Their expertise and dedication to advancing drug-resistant epilepsy care embody exactly why we built this device.
“Consistent with our commercialisation strategy, with each patient enrolled in DETECT, we move closer to our mission: empowering clinicians with objective, continuous brain activity data and ultimately providing the 52 million people living with epilepsy worldwide with the answers, insights, and hope they deserve.”
In June 2025, Epiminder announced the results from the UMPIRE trial, which assessed the Minder system.
